Tuberous sclerosis medical therapy

Jump to navigation Jump to search

Tuberous sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Tuberous sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberous sclerosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberous sclerosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberous sclerosis medical therapy

CDC on Tuberous sclerosis medical therapy

Tuberous sclerosis medical therapy in the news

Blogs on Tuberous sclerosis medical therapy

Directions to Hospitals Treating Tuberous sclerosis

Risk calculators and risk factors for Tuberous sclerosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]

Overview

Medical therapy is generally preferred over surgical ones due to their fewer number of complications and diminishing side effects over time.

Medical Therapy

Epilepsy

  • Anti-seizure medications can be prescribed to control seizures. The preferred medication is vigabatrin[1], but other anticonvulsants, clobazam, ketogenic diet, or surgical procedures.[2] Treatment before the onset of epilepsy and other neuropsychiatric manifestations may be beneficial, but trials testing this approach are still ongoing (EPISTOP trial). mTOR inhibitors may present with some anti-epileptogenic properties.[2]

Lymphangioleiomyomatosis

Angiomyolipoma

  • Treatment is done in a pre-emptive manner to prevent bleeding, reduce tumor size or slow its growth. Systemic everolimus is the preferred method nowadays but there are also surgical options. [2]

Subependymal Giant Cell Astrocytoma

  • Treatment with mTOR inhibitors have been recommended, being well tolerated and presenting with side effects that decreases over time.[2] There are also surgical procedures but they have important complications.

Tuberous Sclerosis Complex-associated Neuropsychiatric Disorder

  • There are no specific interventions, patients must be followed closely by a psychiatrist. Trials exploring the use of mTOR inhibitors for this manifestation are ongoing.[2]

Skin Lesions

For TSC-associated skin lesions, the following treatments may be performed:

  • Sun protection;
  • "Camouflage make-up"
  • Topical mTOR inhibitors.
  • There are surgical options and ablation.

mTOR Inhibitors side effect:

mTOR inhibition therapy may cause stomatitis, diabetes, hyperlipidemia, wound-healing complications, infertility and delayed sexual maturation.[2]

References

  1. Tsao CY (2009). "Current trends in the treatment of infantile spasms". Neuropsychiatr Dis Treat. 5: 289–99. PMC 2695218. PMID 19557123.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Henske, Elizabeth P., et al. "Tuberous sclerosis complex." Nature reviews Disease primers 2.1 (2016): 1-18.